Arcutis Biotherapeutics Inc’s recent filing unveils that its Director Heron Patrick J acquired Company’s shares for reported $34317.0 on May 15 ’25. In the deal valued at $13.62 per share,2,520 shares were bought. As a result of this transaction, Heron Patrick J now holds 17,494 shares worth roughly $0.26 million.
Then, Edwards Larry Todd bought 7,451 shares, generating $104,850 in total proceeds.
Before that, Heron Patrick J bought 6,300 shares. Arcutis Biotherapeutics Inc shares valued at $86,691 were divested by the Director at a price of $13.76 per share. As a result of the transaction, Heron Patrick J now holds 14,974 shares, worth roughly $0.22 million.
H.C. Wainwright initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on December 30, 2024; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Mizuho also remained covering ARQT and has increased its forecast on January 03, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on October 26, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 3.76% to $14.64. Over the last five days, the stock has gained 1.74%. Arcutis Biotherapeutics Inc shares have risen nearly 5.10% since the year began. Nevertheless, the stocks have risen 58.44% over the past one year. While a 52-week high of $17.75 was reached on 03/25/25, a 52-week low of $6.99 was recorded on 02/11/25.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-04-30, growing by 0.51 million shares to a total of 15.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 14.63 million shares. There was a rise of 3.37%, which implies that there is a positive sentiment for the stock.
